dog company fails again, page-12

My understanding is that there is very little reason for Australian investors to buy into this stock prior to the vote and move to the US if that is the outcome.

Many individual investors would not have international trading accounts and many super funds likewise prohibited from trading this (such as Muzzarati's unfortunate experience highlights).

Hence, all of the trading pressure right now would appear to be to the downside.

I believe both Hunter Hall and East Hill have supported the deal, so maybe buying a little to average down the cost of their holdings, but there's little evidence to suggest this is the case.

So, until the deal is done, the price is likely to continue its downward trend which I guess is pretty crappy news for all of us on this side of the Pacific as the merger terms deteriorate further until the outcome next week.

Sadly, like most, I am waayyy negative on my Biota dream, but I am voting 'No' to the merger. Won't make any difference given my pathetic holding, but the company is selling itself short and the timing is terrible in my opinion.

All of this "Australia doesn't understand us" crap, is just that, crap!
Biota was over $3.50 just 3 years ago and over $9 at the turn of the century. Poor management, slow progress, excessive spending and a biotech industry bubble burst have all contrived to where we are today. However, there is no reason that such negative influences are eternal.

Successful Biotechs exist in Australia and if the global markets and Australian bourse do re-energise in 2013, there is much more potential for upside in the small caps than in the blue chips.

Dynamic, charismatic, credible and knowledgeable management are however a pre-requisite.

I would rather stay local - vote out Cook and Lismore, who have not led the organisation sufficiently well for half a decade or so - and bring in new blood to work with Daiichi to close the LANI ROW deal as a dual priority with the BARDA commitments.

Unless I am terribly mistaken, BARDA is not dependent upon a US listing. A US presence, yes. Hence, a competent senior board member needs to be on hand, but I'm not aware that BARDA have obligated Biota on this aspect.
(Happy to hear otherwise, and I can appreciate others' sentiments may strongly differ from mine in this regard).

But ultimately, in my opinion, all of this getting into NASDAQ via the backdoor, using the rotting corpse shell of a failing anti-smoking vaccine enterprise, which will otherwise disappear off the face of the earth, does not fill me with confidence and is a very poor conclusion of a year or so's work from Piper Jaffray and the Biota board.

Let's remember that Jaffray were advisors to both Nabi and Biota prior to this deal, so effectively they seem to have looked no further than what was already in their backyard.
Job well done?
You be the judge.

In my opinion, better options will exist in 12 months' time, including a dual US/AUS or sole US listing if necessary.

The sadistic, mean-spirited, Mr Hyde-side of me, says, hopefully this will be after a harsh northern hemisphere winter - given the last 3 have been very mild from a flu-perspective - and the return of a good pandemic to boot.
(Apologies to all human beings for that ill-will).

Good luck to all and may the stars finally shine and align for us long suffering Biota holders, (preferably before the almighty strikes me down with something terminal) .